Home Neoplasma Ahead of print neo_2026_260427N133

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

neo_2026_260427N133

Title: Baseline circulating tumor plasma cells are associated with progression-free survival in newly diagnosed multiple myeloma: a single-center real-world NGF study
Author: Ján Sýkora, Dominik Kľoc, Bianca Dubiková, Slavomír Kurhajec, Tomáš Guman, Marek Šarišský
Abstract: Circulating tumor plasma cells (CTPCs) in peripheral blood provide a direct readout of myeloma dissemination. While CTPCs are increasingly recognized as prognostically relevant in newly diagnosed multiple myeloma (NDMM), practical cutoffs vary across cohorts and detection methods. Here, we evaluated baseline CTPCs quantified by a single-tube 10-color next-generation flow cytometry (NGF) approach in 55 consecutive patients with symptomatic treatment-indicated NDMM. Progression-free survival (PFS) from diagnosis was analyzed using Kaplan–Meier method and compared across pragmatic CTPCs cutoffs (0.02%, 0.05%, and 0.07%) and the cohort median (0.0159%). The median follow-up by reverse Kaplan–Meier analysis was 27.9 months (interquartile range IR 20.2–31.9). The recently proposed 0.02% CTPCs threshold showed a non-significant PFS separation (median PFS 27.3 vs. 40.3 months for >0.02% vs. ≤0.02%; log-rank p=0.068; hazard ratio HR 2.23, 95% confidence interval CI 0.92–5.42). CTPCs dichotomized at 0.05% significantly stratified PFS (log-rank p=0.007), whereas 0.07% and the median cutoff yielded borderline separation. Patients with >0.05% CTPCs at diagnosis showed a significantly shorter PFS compared to those with ≤0.05% CTPCs (median PFS 14.3 vs. 40.3 months). Patients with >0.05% CTPCs were at a significantly higher risk of event (HR 3.07, 95% CI 1.29–7.31, p=0.011). Peripheral blood normal plasma cells and bone marrow tumor plasma cells showed additional associations with PFS, while bone marrow normal plasma cells did not. R2-ISS stage and high-risk cytogenetics did not stratify PFS in this cohort. To conclude, these findings support the clinical relevance of baseline CTPCs quantification in real-world NDMM, but this small single-center cohort does not formally validate any specific cutoff or establish a new clinical cutoff.
Keywords: newly diagnosed multiple myeloma; circulating tumor plasma cells; next-generation flow cytometry; peripheral blood; prognosis; progression-free survival
Year: , Volume: , Issue: Page From: , Page To:
doi:10.4149/neo_2026_260427N133


download file


© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.